08/18/2026 | Companies

AFC, AK0406, antigenic drift, antiviral drug, antiviral drug-Fc conjugate, antiviral therapy, ArkBio, Australia, biopharmaceuticals, China, clinical development, drug development, global clinical development, HREC, IND approval, infectious diseases, influenza, influenza A, influenza B, influenza prevention, influenza prophylaxis, influenza vaccines, long-acting antiviral, NMPA, Phase I clinical trial, preclinical studies, prophylactic treatment, seasonal influenza, Shanghai Ark Biopharmaceutical, therapeutic treatment